Clinical trial
A Comparative Phase IV Study Evaluating Efficacy & Safety Of…
NCT00360607 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00360607 |
|---|---|
| Title | A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections |
| Official title | A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Infection |
| Intervention type | Drug |
| Interventions | Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd., Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited, Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd., Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd. |
| Enrollment | 307 |
| Start date | Jul 1, 2004 |
| Completion | Apr 1, 2005 |
| First posted | Aug 4, 2006 |
| Last update posted | Dec 2, 2008 |
| Countries | India |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: